68Ga-BBN-RGD PET/CT for GRPR and Integrin αvβ3 Imaging in Patients with Breast Cancer
Open accessAbstract
Purpose: This study was to assess a gastrin-releasing peptide receptor (GRPR) and integrin αvβ3 dual targeting tracer 68 Ga-BBN-RGD for positron emission tomography (PET)/computed tomography (CT) imaging of breast cancer and metastasis.Materials and Methods: Twenty-two female patients were recruited either with suspected breast cancer on screening mammography (n = 16) or underwent breast cancer radical mastectomy (n = 6).All the 22 patients underwent PET/CT at 30-45 min after intravenous injection of 68 Ga-BBN-RGD.Eleven out of 22 patients also accepted 68 Ga-BBN PET/CT within 2 weeks for comparison.A final diagnosis was made based on the histopathologic examination of surgical excision or biopsy.Results: Both the primary cancer and metastases showed positive 68 Ga-BBN-RGD accumulation.The T/B ratios of 68 Ga-BBN-RGD accumulation were 2.10 to 9.44 in primary cancer and 1.10 to 3.71 in axillary lymph node metastasis, 3.80 to 10.7 in distant lymph nodes, 2.70 to 5.35 in lung metastasis and 3.17 to 22.8 in bone metastasis, respectively.For primary lesions, the SUVmax from 68 Ga-BBN-RGD PET in ER positive group was higher than that in ER negative group (P < 0.01).For both primary and metastatic lesions, SUVmean quantified from 68 Ga-BBN-RGD PET correlated well with both GRPR expression and integrin αvβ3 expression.Conclusion: This study demonstrated significant uptake of a new type of dual integrin αvβ3 and GRPR targeting radiotracer in both the primary lesion and the metastases of breast cancer.68 Ga-BBN-RGD PET/CT may be of great value in discerning both primary breast cancers, axillary lymph node metastasis and distant metastases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Due to overexpression of αvβ3 integrin receptors on tumor vasculature, nanoparticles decorated with RGD peptide have more access to targeted tumor tissues.
“For example, due to the overexpression of αvβ3 integrin receptors on tumor vasculature, the nanoparticles decorated with arginine-glycine-glutamic acid (RGD) peptide, a ligand for αvβ3 integrin receptors, have more access to the targeted tumor tissues [163–165].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606 · see citing works
Screening for breast cancer with mammography
Gøtzsche, P. C., & Jørgensen, K. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001877.pub5 · Cited by 1,884 · see citing works
Role of integrins in cell invasion and migration
Hood, J. D., & Cheresh, D. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc727 · Cited by 1,781 · see citing works
Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations
Elmore, J. G., Barton, M. B., Moceri, V. M., Polk, S., Arena, P. J., & Fletcher, S. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804163381601 · Cited by 1,051 · see citing works
Gastrin-Releasing Peptide Receptors in Non-Neoplastic and Neoplastic Human Breast
Gugger, M., & Reubi, J. C. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65525-3 · Cited by 248 · see citing works
Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer
Kumar, R., Chauhan, A., Zhuang, H., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9159-2 · Cited by 226 · see citing works
Prasanphanich, A. F., Nanda, P. K., Rold, T. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705347104 · Cited by 213 · see citing works
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
Mansi, R., Wang, X., Forrer, F., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1596-9 · Cited by 205 · see citing works
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes
Smith, C. J., Volkert, W. A., & Hoffman, T. J. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.05.005 · Cited by 182 · see citing works
Why Integrin as a Primary Target for Imaging and Therapy
Niu, G., & Chen, X. S. (2011) · Theranostics · doi:10.7150/thno/v01p0030 · Cited by 179 · see citing works
Self-citationBeer, A. J., Niemeyer, M., Carlsen, J., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045526 · Cited by 174 · see citing works
Chen, X., Park, R. J.-H., Hou, Y., et al. (2004) · PubMed · Cited by 159 · see citing works
Self-citation18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging
Li, Z., Wu, Z., Chen, K., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048009 · Cited by 148 · see citing works
Beer, M., Montani, M., Gerhardt, J., Wild, P. J., Hany, T. F., Hermanns, T., Müntener, M., & Kristiansen, G. (2011) · The Prostate · doi:10.1002/pros.21434 · Cited by 146 · see citing works
18F, 64Cu, and 68Ga Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of Breast Cancer
Liu, Z., Yan, Y., Liu, S., et al. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9000245 · Cited by 142 · see citing works
Mittra, E., Goris, M. L., Iagaru, A. H., et al. (2011) · Radiology · doi:10.1148/radiol.11101139 · Cited by 128 · see citing works
Stoykow, C., Erbes, T., Maëcke, H. R., et al. (2016) · Theranostics · doi:10.7150/thno.14958 · Cited by 128 · see citing works
FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations
Lim, H. S., Yoon, W., Chung, T. W., Kim, J. K., Park, J. G., Kang, H. K., Bom, H. S., & Yoon, J. H. (2007) · Radiographics · doi:10.1148/rg.27si075507 · Cited by 121 · see citing works
Eder, M., Schäfer, M. K.-H., Bauder‐Wüst, U., et al. (2014) · The Prostate · doi:10.1002/pros.22784 · Cited by 120 · see citing works
F-18 FDG Uptake in Breast Infection and Inflammation
BAKHEET, S. M. B., Powe, J., Kandil, A., Ezzat, A. A., Rostom, A. Y., & Amartey, J. K. (2000) · Clinical Nuclear Medicine · doi:10.1097/00003072-200002000-00003 · Cited by 120 · see citing works
Morgat, C., MacGrogan, G. M., Brouste, V., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188011 · Cited by 118 · see citing works
Μάινα, Θ., Bergsma, H., Kulkarni, H., Müeller, D., Charalambidis, D., Krenning, E. P., Nock, B. A., de Jong, M., & Baum, R. P. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3232-1 · Cited by 112 · see citing works
Zhang, J., Niu, G., Lang, L., Li, F., Fan, X., Yan, X., Yao, S., Yan, W., Huo, L., Chen, L., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177048 · Cited by 93 · see citing works
Self-citation18F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging
Yang, M., Gao, H., Zhou, Y., et al. (2011) · Theranostics · doi:10.7150/thno/v01p0220 · Cited by 82 · see citing works
Sah, B.-R., Burger, I. A., Schibli, R., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147116 · Cited by 70 · see citing works
68Ga-NOTA-Aca-BBN(7–14) PET/CT in Healthy Volunteers and Glioma Patients
Zhang, J., Li, D., Lang, L., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.165316 · Cited by 70 · see citing works
Self-citationRaikhlin, A., Curpen, B. N., Warner, E., Betel, C., Wright, B. A., & Jong, R. A. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.13.12264 · Cited by 69 · see citing works
18F-AmBF3-MJ9: A novel radiofluorinated bombesin derivative for prostate cancer imaging
Pourghiasian, M., Liu, Z., Pan, J., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.009 · Cited by 59 · see citing works
Review: Receptor Targeted Nuclear Imaging of Breast Cancer
Dalm, S. U., Verzijlbergen, J. F., & de Jong, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020260 · Cited by 37 · see citing works
GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs
Carlucci, G., Kuipers, A., Ananias, H. J. K., et al. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.004 · Cited by 36 · see citing works
Updated results of the Gothenburg Trial of Mammographic Screening
Bjurstam, N., Björneld, L., & Duffy, S. W. (2016) · Cancer · doi:10.1002/cncr.29975 · Cited by 34 · see citing works
FDG-PET in Breast Cancer A Different View of its Clinical Usefulness
Czernin, J. (2002) · Molecular Imaging and Biology · doi:10.1016/s1095-0397(01)00069-3 · Cited by 33 · see citing works
Molecular Imaging and Precision Medicine in Breast Cancer
Chudgar, A. V., & Mankoff, D. A. (2016) · PET Clinics · doi:10.1016/j.cpet.2016.08.001 · Cited by 20 · see citing works
Inadvisable breast and prostate cancer screenings in the USA
Granovetter, M. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00069-3 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [26]Maina T Bergsma H Kulkarni HR Mueller D Charalambidis D Krenning EP Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT Eur J Nucl Med Mol Imaging 2016 43 964 73 26631238
- [31]Liu Z Yan Y Liu S Wang F Chen X 18F, 64Cu, and 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer Bioconjugate Chem 2009 20 1016 25 PMC2895820 20540537
Cited by
Sorted by citations
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · see citing works
Self-citation
- Authors
- Zhang, J., Mao, F., Niu, G., Peng, L., Lang, L., Li, F., Ying, H., Wu, H., Pan, B., Zhu, Z., & Chen, X.
- Affiliations
- National Institutes of Health (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Zhang, Jingjing
- Mao, Feng
- ORCID
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 4
- Pages
- 1121-1130
- ISSN
- 1838-7640 (ISSN-L)
- PMC
- PMC5817114
- OpenAlex
- W2794043418
- Cited by
- 95
- References
- 35
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 9 · 2023: 6 · 2022: 18 · 2021: 10 · 2020: 17 · 2019: 10 · 2018: 3
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Theranostics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (2016-1, 81171369, 81171370, 81271614)
- Peking Union Medical College Hospital
- Peking Union Medical College
- National Institutes of Health
- National Institute of Biomedical Imaging and Bioengineering
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Keywords
- gastrin-releasing peptide receptor, integrin αvβ3, breast cancer, metastasis imaging, axillary lymph node metastasis, lung metastasis, bone metastasis, tumor-to-background ratio, estrogen receptor status, PET/CT
- MeSH terms
- Positron Emission Tomography Computed Tomography, Adult, Bombesin, Breast Neoplasms, Female, Gallium Radioisotopes, Humans, Middle Aged, Oligopeptides, Receptors, Bombesin, Integrin alphaVbeta3, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
